Novartis buys Myricx Bio in $1.5bn deal
Swiss drug and health care company Novartis has acquired London based biotech Myricx Bio in a deal valued at up to $1.5bn Announced on July 6, the deal comprises a substantial $1.1bn upfront cash payment and $400 million in potential milestones. The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals. Myricx Bio…
Isomorphic Labs closes $2.1bn funding round
Isomorphic Labs, the London based artificial intelligence specialist spun out of Google DeepMind, has secured $2.1bn billion dollars in a Series B funding round to accelerate its work on drug discovery. This capital injection marks a significant milestone for the drug design sector and highlights growing investor confidence in the application of generative AI within the life sciences and healthcare…
Novartis expands clinical pipeline with multi-billion dollar acquisitions
Novartis has expanded its clinical pipeline through the back to back acquisitions of Pikavation Therapeutics and Excellergy. The Swiss pharmaceutical giant is seeking to offset looming patent expiries for major brands such as Entresto and Promacta. The first transaction involves the acquisition of Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, for $3bn. Under the definitive agreement, Novartis will pay $2bn…
Novartis acquires biopharmaceutical group Avidity for $12bn
Global pharmaceutical and healthcare company Novartis has agreed to acquire biopharmaceutical company Avidity Biosciences for around $12 billion . The transaction is expected to close in the first half of 2026 and follows Avidity’s separation of its early-stage precision cardiology programs into a new publicly traded entity SpinCo. The move significantly strengthens Novartis’ neuroscience franchise by adding three late-stage neuromuscular…